TY - JOUR
T1 - Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements
AU - Frauenfeld, Leonie
AU - Castrejon-De-Anta, Natalia
AU - Ramis-Zaldivar, Joan Enric
AU - Streich, Sebastian
AU - Salmeron-Villalobos, Julia
AU - Otto, Franziska
AU - Mayer, Annika Katharina
AU - Steinhilber, Julia
AU - Pinyol, Magda
AU - Mankel, Barbara
AU - Ramsower, Colleen
AU - Bonzheim, Irina
AU - Fend, Falko
AU - Rimsza, Lisa M.
AU - Salaverria, Itziar
AU - Campo, Elias
AU - Balague, Olga
AU - Quintanilla-Martinez, Leticia
N1 - Funding Information:
This work was supported in part by the Deutsche Forschungs-gemeinschaft (DFG) under Germany's Excellence Strategy (iFIT) EXC2180-390900677 (L.Q.-M.); the Ministerio de Ciencia e Innovación (MCI) grant No. RTI2018-094274-B-I00 (E.C.); EDER: European Regional Development Fund “Una manera de hacer Europa” and Generalitat de Catalunya Suport Grups de Recerca AGAUR grant Nos. 2017-SGR-1142 (E.C.) and 2017-SGR-1107 (I.S.); Acció instrumental d’incorporació de científics i tecnòlegs PERIS 2016 (SLT002/16/00336) and Asociación Española Contra el Cáncer (AECC CICPFI6025SALA) (I.S.). E.C. is an academia researcher of the Institució Catalana de Recerca I Estudis Avanc¸ats of the Generalitat de Catalunya (ICREA). I.S. is a Miguel Servet researcher (CPII18/00015) from Instituto de Salud Carlos III.
Publisher Copyright:
ß 2022 by The American Society of Hematology.
PY - 2022/4/12
Y1 - 2022/4/12
N2 - Diffuse large B-cell lymphoma (DLBCL) with aberrant coexpression of CD101BCL61MUM11 (DLBCL-AE), classified as germinal center B cell (GCB) type by the Hans algorithm (HA), was genetically characterized. To capture the complexity of DLBCL-AE, we used an integrated approach that included gene expression profiling (GEP), fluorescence in situ hybridization, targeted gene sequencing, and copy number (CN) arrays. According to GEP, 32/54 (59%) cases were classified as GCB-DLBCL, 16/54 (30%) as activated B-cell (ABC) DLBCL, and 6/54 (11%) as unclassifiable. The discrepancy between HA and GEP was 41%. Three genetic subgroups were identified. Group 1 included 13/50 (26%) cases without translocations and mainly showing and ABC/MCD molecular profile. Group 2 comprised 11/50 (22%) cases with IRF4 alterations (DLBCL-IRF4), frequent mutations in IRF4 (82%) and NF-kB pathway genes (MYD88, CARD11, and CD79B), and losses of 17p13.2. Five cases each were classified as GCB- or ABC-type. Group 3 included 26/50 (52%) cases with 1 or several translocations in BCL2/BCL6/MYC/IGH, and GCB/ EZB molecular profile predominated. Two cases in this latter group showed complex BCL2/ BCL6/IRF4 translocations. DLBCL-IRF4 in adults showed a similar copy number profile and shared recurrent CARD11 and CD79B mutations when compared with LBCL-IRF4 in the pediatric population. However, adult cases showed higher genetic complexity, higher mutational load with frequent MYD88 and KMT2D mutations, and more ABC GEP. IRF4 mutations were identified only in IRF4-rearranged cases, indicating its potential use in the diagnostic setting. In conclusion, DLBCL-AE is genetically heterogeneous and enriched in cases with IRF4 alterations. DLBCL-IRF4 in adults has many similarities to the pediatric counterpart.
AB - Diffuse large B-cell lymphoma (DLBCL) with aberrant coexpression of CD101BCL61MUM11 (DLBCL-AE), classified as germinal center B cell (GCB) type by the Hans algorithm (HA), was genetically characterized. To capture the complexity of DLBCL-AE, we used an integrated approach that included gene expression profiling (GEP), fluorescence in situ hybridization, targeted gene sequencing, and copy number (CN) arrays. According to GEP, 32/54 (59%) cases were classified as GCB-DLBCL, 16/54 (30%) as activated B-cell (ABC) DLBCL, and 6/54 (11%) as unclassifiable. The discrepancy between HA and GEP was 41%. Three genetic subgroups were identified. Group 1 included 13/50 (26%) cases without translocations and mainly showing and ABC/MCD molecular profile. Group 2 comprised 11/50 (22%) cases with IRF4 alterations (DLBCL-IRF4), frequent mutations in IRF4 (82%) and NF-kB pathway genes (MYD88, CARD11, and CD79B), and losses of 17p13.2. Five cases each were classified as GCB- or ABC-type. Group 3 included 26/50 (52%) cases with 1 or several translocations in BCL2/BCL6/MYC/IGH, and GCB/ EZB molecular profile predominated. Two cases in this latter group showed complex BCL2/ BCL6/IRF4 translocations. DLBCL-IRF4 in adults showed a similar copy number profile and shared recurrent CARD11 and CD79B mutations when compared with LBCL-IRF4 in the pediatric population. However, adult cases showed higher genetic complexity, higher mutational load with frequent MYD88 and KMT2D mutations, and more ABC GEP. IRF4 mutations were identified only in IRF4-rearranged cases, indicating its potential use in the diagnostic setting. In conclusion, DLBCL-AE is genetically heterogeneous and enriched in cases with IRF4 alterations. DLBCL-IRF4 in adults has many similarities to the pediatric counterpart.
UR - http://www.scopus.com/inward/record.url?scp=85129332368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129332368&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021006034
DO - 10.1182/bloodadvances.2021006034
M3 - Article
C2 - 34654055
AN - SCOPUS:85129332368
SN - 2473-9529
VL - 6
SP - 2361
EP - 2372
JO - Blood advances
JF - Blood advances
IS - 7
ER -